OKYO Pharma Ltd
OKYO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OKYO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OKYO
OKYO Pharma Ltd is a clinical-stage biotechnology company developing urcosimod for neuropathic corneal pain and other corneal diseases, facing significant financial and clinical uncertainties.
Key risk: Going concern uncertainty
Market Cap
$87.6M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jul 31, 2025.
Tracking 1 clinical trial for OKYO Pharma Ltd.
OKYO Pharma Ltd is a clinical-stage biotechnology company developing urcosimod for neuropathic corneal pain and other corneal diseases, facing significant financial and clinical uncertainties.
- OKYO Pharma is focused on developing urcosimod for neuropathic corneal pain (NCP) and other corneal and anterior segment diseases [sec · filed 2026-07-20].
- As of March 31, 2026, the company had an accumulated deficit of $152 million, a net loss of $8.9 million for the year, and cash and equivalents of $20.6 million [sec · filed 2026-07-20].
- The company has experienced recurring losses and expects to continue incurring losses, requiring additional capital to complete development and commercialization [sec · filed 2026-07-20].
- OKYO also invests in other product candidates, such as OK-201, but faces risks of limited market acceptance and competition [sec · filed 2026-07-20].
What works
- OKYO has a lead product candidate, urcosimod, targeting neuropathic corneal pain, a condition with unmet medical need [sec · filed 2026-07-20].
- The company has cash flow projections that, based on certain assumptions, indicate sufficient resources to continue as a going concern [sec · filed 2026-07-20].
- OKYO has ongoing clinical trials and research activities that could advance its pipeline if successful [sec · filed 2026-07-20].
What to weigh
- OKYO has a significant accumulated deficit of $152 million as of March 31, 2026, and has incurred net losses and negative cash flows from operations [sec · filed 2026-07-20].
- The company faces substantial doubt about its ability to continue as a going concern without raising additional funding, as noted in the 2025 filing [sec · filed 2025-07-18].
- The development and commercialization of urcosimod are highly uncertain, depending on successful clinical trials, regulatory approvals, and market acceptance [sec · filed 2026-07-20].
- OKYO will need to raise additional capital to complete development, and such financing may not be available on favorable terms [sec · filed 2026-07-20].
From the filings
Quoted directly from source documents.
The company has a large accumulated deficit and ongoing losses.
“as of March 31, 2026, had an accumulated deficit of $ 152 m ($ 109 m of this accumulated loss relates to a discontinued business prior to the reorganisation in 2018), a net loss for the year ended March 31, 2026, of $ 8.9 m and net cash used in operating activities for the year ended March 31, 2026, of $ 5.9 m.”
SEC filings · July 20, 2026
There is substantial doubt about the company's ability to continue as a going concern without additional funding.
“The Directors have prepared cash flow projections that include the costs associated with the continued clinical trials and additional investment to fund that operation. On the basis of those projections, the directors conclude that, without raising additional funding, the company will not be able to initiate the next phase of trials and meet its liabilities as they fall due within the next 12 months from the date when these financial statements are issued.”
SEC filings · July 18, 2025
The company's product candidates are in early stages and face significant risks.
“Our product candidates are in the early”
SEC filings · July 20, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue without additional funding, as per 2025 filing [sec · filed 2025-07-18].
- Clinical and regulatory risk — Urcosimod development depends on successful trials and approvals, which are uncertain [sec · filed 2026-07-20].
- Financing risk — Need for additional capital may not be available on favorable terms, diluting shareholders [sec · filed 2026-07-20].
- Commercialization risk — Even if approved, urcosimod may face limited market acceptance or competition [sec · filed 2026-07-20].
What to watch
- Progress and results of clinical trials for urcosimod in neuropathic corneal pain [sec · filed 2026-07-20].
- Ability to raise additional capital to fund ongoing operations and next-phase trials [sec · filed 2025-07-18].
- Regulatory developments and any marketing approvals for urcosimod [sec · filed 2026-07-20].
- Cash burn rate and updates to cash runway projections [sec · filed 2026-07-20].
Sources: SEC filings · Generated August 27, 2026 · How we verify sources →
Run OKYO Pharma Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available OKYO Pharma Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$2.9M
| Holder | Shares | Value |
|---|---|---|
| maven securities ltd | 1,175,535 | $1.9M |
| balyasny asset management l.p. | 584,796 | $942K |
| xtx topco ltd | 37,652 | $61K |
| geode capital management, llc | 12,090 | $19K |
| osaic holdings, inc. | 152 | $244 |
| morgan stanley | 10 | $16 |
Short Interest
as of Apr 20, 2026- % of float
- 0.5%
- Days to cover
- 1.9
- Shares short
- 206,345
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OKYO short interestFrequently asked questions
What is the AI investment thesis for OKYO Pharma Ltd?
OKYO Pharma Ltd is a clinical-stage biotechnology company developing urcosimod for neuropathic corneal pain and other corneal diseases, facing significant financial and clinical uncertainties.
Who is the CEO of OKYO Pharma Ltd?
Mr. Robert J. Dempsey M.B.A. is the chief executive officer of OKYO Pharma Ltd (OKYO).
Where is OKYO Pharma Ltd headquartered?
OKYO Pharma Ltd (OKYO) is headquartered in London, United Kingdom.
What therapeutic areas does OKYO Pharma Ltd focus on?
OKYO Pharma Ltd develops therapies across Neurology, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.